We are currently making some changes to how orders are placed and because of this there will be a
short disruption period affecting order processing. Thank you for your patience while we work to
operate as smoothly as possible (November 14, 2023).
UOXFi007-A
MK002-4
iPSC line
Purchases have been temporarily disabled, as we are transitioning sales and distribution.
If you are interested in purchasing this cell line, please contact EBiSC directly. For more information about the current transition process see here.
If you are interested in purchasing this cell line, please contact EBiSC directly. For more information about the current transition process see here.
A CLIP contains information about a cell line including any
specific third party obligations relating to, for example,
licensing obligations or the donor consent which affect the
use of the cell line.
The EBiSC Access and Use Agreement must be completed along with an individual
Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org
for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
Cell Line |
|
hPSCreg Name | UOXFi007-A |
Alternative name(s) |
MK002-4
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
STBCi004-B-1 (SFC832-03-06 LRRK2WT/WT C47) Donor's gene variants: LRRK2 Donor diseases: Parkinson disease EDi001-A-2 (AST23-1KO-3, AST22-1KO-3, AST-23_SCAKO Clone 3, AST-22_SNCAKO Clone 3) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-3 (AST23_SNCAKO Clone 1, AST22-1KO-1, AST23-1KO-1, AST22_SNCAKO Clone 1) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A (AST22, AST23, SAMEA3319992) Donor's gene variants: SNCA, SNCA, SNCA Donor diseases: Parkinson disease |
Provider |
|
Depositor | University of Oxford (UOXF) |
Distributors |
EBiSC
European Collection of Authenticated Cell Cultures (ECACC)
|
External Databases |
|
hPSCreg | UOXFi007-A |
BioSamples | SAMEA103988274 |
Cellosaurus | CVCL_LE37 |
CLO | CLO_0101642 |
Wikidata | Q54991451 |
General Information |
|
Publications | View all related publications on hPSCreg (1) |
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information#
General Donor Information |
|
Sex | female |
Age of donor (at collection) | 70-74 |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
Other cell lines of this donor | |
All cell lines of this donor's relatives |
Has daughter:
|
External Databases (Donor) |
|
BioSamples | SAMEA103887563 |
hIPSC Derivation#
General |
|
Source cell type |
fibroblast of dermis |
Source cell origin |
zone of skinAny portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
Synonyms
|
Age of donor (at collection) | 70-74 |
Collected in | 2011 |
Passage number reprogrammed | 4 |
Reprogramming method |
|
Vector type | Integrating |
Vector | Virus (Retrovirus) |
Genes | |
Is the used vector excisable? |
Unknown |
Absence of reprogramming vector(s)? |
Unknown |
Reprogramming vectors silenced? |
Yes |
Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
Selection criteria for clones | Morphology |
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions#
Latest released batch |
|
Culture medium | mTeSR |
Passage method | EDTA |
Surface coating | Matrigel / Geltrex |
O2 concentration | 20 |
CO2 concentration | 5 |
Temperature | 37 |
The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating | Matrigel/Geltrex | ||||||
Feeder cells |
No |
||||||
Passage method |
Enzyme-free cell dissociation
EDTA
|
||||||
O2 Concentration | 21 % | ||||||
CO2 Concentration | 5 % | ||||||
Medium |
Essential 8™
Supplements
|
||||||
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
||||||
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
||||||
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation#
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
TRA 1-60 |
Yes |
|||||
NANOG |
Yes |
|||||
SSEA-4 |
Yes |
|
||||
SSEA-1 |
No |
|
Pluripotency Score | Novelty Score | |
21.44 | 1.4 |
Report
Microbiology / Virus Screening |
|
HIV 1 | Negative |
HIV 2 | Negative |
Hepatitis B | Negative |
Hepatitis C | Negative |
Mycoplasma | Negative |
Sterility |
|
Inoculation for microbiological growth | No Contaminants Detected |
Mycoplasma | Not Detected |
Viability | Viable post-cryopreservation |
Genotyping#
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Is there genome-wide genotyping or functional data available? |
Yes
Whole genome sequencing
https://ega-archive.org/studies/EGAS00001002755 This cell line has undergone WGS using the Illumina HiSeq X platform at 30x coverage. Fastq files are stored at the European Genome Archive, users can apply for access to this data by submitting an application form to the EBiSC Data Access Committee https://ega-archive.org/dacs/EGAC00001000768 |